Back in November 2012 we invested in Maxygen (MAXY) based on a simple premise. The company was in the process of liquidating and returning capital to the shareholders, and had no ongoing operations. Since they had more cash sitting on the books than the market value of the company, some return was guaranteed. Without any [...]
MAXY – Maxygen, Inc.
Maxygen, Inc., a biopharmaceutical company, engages in developing various products in the field of human therapeutics in North America. It focuses on the development of MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.